The US Food and Drug Administration (FDA) has approved Lannett’s abbreviated new drug application (ANDA) of Loxapine Capsules in 5mg, 10mg, 25mg and 50mg doses.

Loxapine Capsules are therapeutically equivalent to Watson Pharmaceuticals’ Loxitane Capsules.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The company expects to start commercialising the product in the next few weeks.

Lannett president and CEO Arthur Bedrosian said they have now received five product approvals from the FDA over the last three months.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now